Video Experimental Relacionado
Updated: Jan 24, 2026
18:48
In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
Published on: August 12, 2017
14.9K
Farmacoterapia anti-obesidad para receptores de trasplantes
Christine E Haugen1, Babak J Orandi2
1Department of Surgery, University of Cincinnati, Cincinnati, OH, USA.
Current atherosclerosis reports
|January 23, 2026
Resumen
Los medicamentos contra la obesidad, incluidos los agonistas de las hormonas estimuladas por nutrientes (NuSH), son prometedores para los receptores de trasplantes. Se necesita más investigación para guiar su uso y mejorar la supervivencia a largo plazo en esta población de alto riesgo.
Área de la Ciencia:
- Medicina de trasplantes; Farmacología; Manejo de la obesidad
Sus antecedentes:
- La obesidad es prevalente en receptores de trasplantes de hígado (hasta 40%) y riñón (33%).
- El aumento de peso postrasplante es común y se asocia con peores resultados, incluida una menor supervivencia del alotrasplante y un mayor riesgo cardiovascular.
- El uso de farmacoterapia contra la obesidad es limitado en las poblaciones de trasplantes a pesar de la alta necesidad.
Objetivo del estudio:
- Revisar las opciones de farmacoterapia contra la obesidad para receptores de trasplantes de hígado y riñón.
- Guiar el uso de estos medicamentos en este grupo específico de pacientes.
Principales métodos:
- Revisión de las opciones actuales de farmacoterapia contra la obesidad.
- Análisis de los datos existentes sobre el uso de medicamentos en receptores de trasplantes.
Principales resultados:
- Los medicamentos de hormonas estimuladas por nutrientes (NuSH), como los agonistas del receptor de péptidos similar al glucagón-1 (GLP-1) y los agonistas duales de los receptores de GLP-1/péptido insulinotrópico dependiente de glucosa (GIP), son eficaces para la obesidad y la reducción del riesgo cardiovascular en la población general.
- Estos agentes son de interés para el manejo de la obesidad en receptores de trasplantes.
- Existen datos limitados sobre su eficacia y seguridad en receptores de trasplantes de hígado y riñón.
Conclusiones:
- Los medicamentos contra la obesidad, en particular los agonistas de NuSH, pueden ofrecer beneficios para los receptores de trasplantes.
- La investigación adicional, incluidos los ensayos controlados aleatorios, es crucial.
- La integración de la experiencia en medicamentos para la obesidad en la atención de trasplantes de rutina es esencial para mejorar la supervivencia a largo plazo del injerto y del paciente.
Videos de Conceptos Relacionados
01:26Psychosis: Goals of Pharmacotherapy
480
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
480
01:15Diabetes: Management and Pharmacotherapy
883
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
883
01:24Obesity
1.2K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.2K
01:21Drug Dosing: Obese Patients
238
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
238
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
260
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
260
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
175
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
175